COGT logo

COGENT BIOSCIENCES INC

COGTNASDAQ
🏆 #1178 by market capEarnings Nov 10US Equity
$32.13▼ $0.12 (−0.36%)
Latest quote
🔔
Track COGT
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.4%
7d▲ 2.6%
14d▲ 8.8%
30d▲ 1.5%
ytd▼ 9.5%
1y▲ 100.9%
🏦Market Cap
$5.58B
Small Cap
📈Revenue Growth (YoY)
0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
44
Weak

Trading Snapshot

Day Range
$32.06 – $32.82
52-Week Range
$13.78 – $43.73
Volume (shares)
24,737
Avg Volume (shares)
—
Shares Outstanding
173.5M
Next Earnings
2026-11-10

Fundamentals Snapshot

Annual Revenue
—
Last Q Revenue
—
P/E Ratio
-14.0
P/S Ratio
0.0x
EPS (TTM)
$-2.21
Dividend Yield
0.00%
Dilution (1yr)
+45.7%
COGT logo

COGENT BIOSCIENCES INC

COGT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$333M▲ +20.8% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$266M▲ +27.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
161.0M▲ +45.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$59M▼ −$22M YoY
StockOtter · stockotter.space

About COGENT BIOSCIENCES INC

Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
44/100

Analyst Ratings

ⓘ
Consensus
Buy
18 analysts
Strong Buy8
Buy8
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.